This allows novel targets to be rapidly and efficiently pursued to treat glomerular diseases, as well as the ability to deliver any genetic material with high efficiency to be expressed specifically in podocytes with a reduced dose and improved patient safety.

The Purespring platform also includes a capsid with tropism for podocytes and robust CMC processes for the whole product pipeline, offering long-term time, cost and regulatory benefits.

We are actively looking for partners in the kidney space interested in collaborating to maximize the benefits of our technology and bring new treatments patients living with kidney disease.